Nurtec ODT (Rimegepant)

No generic rimegepant is approved; the latest Nurtec ODT patent or exclusivity in the Orange Book runs to 03/25/2039. 1 staged generic application passed FDA review and waits on patents or exclusivity.

Nurtec ODT was first approved by the FDA on 02/27/2020 under NDA 212728; the application holder is Pfizer Inc.

The latest NADAC for NURTEC ODT 75 MG TABLET is $128.66 per unit (as of 10/28/2026).

Holder Pfizer IncApplication NDA 212728Approved 02/27/2020

Open full profile Start free trial

Data as of 10/31/2026

Market protectionProtected12 yr 4 moLatest patent 03/25/2039 Generics0 makers1 staged, awaiting entry FDA shortageClearNot listedCurrent FDA list NADAC$128.66 / unitAs of 10/28/2026

01Patents and exclusivity

When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.

4,528days until the latest patent expires

ExclusivityPatent onlyOpen to generics

Today

Approved02/27/2020

Last patent03/25/2039

2021202420272030203320362039

Latest patent: 03/25/2039Nurtec ODT

02Competition

Generics: No generic approved
Staged generics: 1 passed FDA review, awaiting market entry

Every listingEach listing and maker behind the generics count.

Price erosionHow NADAC moves as generics enter.

PrescribersWho prescribes it, from Medicare data.

Available in the full Nurtec ODT profile.See what is included

03Supply and price

FDA drug shortage: ClearNot on the current shortage list
NADAC: $128.66 per unitNURTEC ODT 75 MG TABLET, as of 10/28/2026

04Product

Application holder: Pfizer Inc
Application: NDA 212728
First approved: 02/27/2020
Dosage forms: tablet, orally disintegrating
Routes: oral

Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.